A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Evaluation of the Efficacy and Safety of Once-Daily Administrations of TZP-102 for the Treatment of Symptoms Associated With Diabetic Gastroparesis.
Phase of Trial: Phase II
Latest Information Update: 28 Aug 2014
At a glance
- Drugs TZP 102 (Primary)
- Indications Diabetic gastroparesis
- Focus Therapeutic Use
- Sponsors Tranzyme Pharma
- 15 Nov 2012 Preliminary top-line results, indicating the trial did not meet the primary endpoint, were published in a Tranzyme Pharma media release.
- 15 Nov 2012 Primary endpoint 'Gastroparesis-Symptom-Daily-Diary composite score' has not been met.
- 01 Nov 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History